Preparation, Characterization and Evaluation of Quetiapine Fumarate Solid Lipid Nanoparticles to Improve the Oral Bioavailability

Table 2

Size, PDI, ZP, total drug content and EE of various formulations.

Formulation code	Size (nm) ± SD	PDI ± SD	ZP (mV) ± SD	Total drug content (mg) ± SD	EE (%) ± SD
F1	167.8±11.87	0.441±0.01	−23.9±1.87	9.52±0.01	89.23±0.10
F2	194.23±2.89	0.310±0.01	−22.7±1.78	9.11±0.07	90.08±0.24
F3	174.73±4.47	0.305±0.09	−28.1±2.16	9.60±0.02	91.56±0.30
F4	207.16±5.79	0.230±0.01	−26.3±2.06	9.23±0.01	92.06±0.09
F5	245.30±4.92	0.241±0.03	−19.9±1.56	9.04±0.00	82.38±0.21
F6	271.76±8.52	0.280±0.08	−18.5±1.45	9.40±0.03	84.26±0.25